Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2019-10-22 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
PR_2019-10-22_BT_EGM3_2019-11-22_Notice_EN_Final.pdf
AGM Information Classification · 95% confidence The document is a formal announcement dated October 22, 2019, stating that the preliminary documents for an Extraordinary General Shareholder Meeting (EGM) scheduled for November 22, 2019, have been made available. It explicitly mentions that the notice for the meeting, including the agenda and motions to vote, is published, and the documents can be consulted on the company website or requested. This structure—announcing the availability of materials for an upcoming shareholder meeting—strongly aligns with the purpose of a Proxy Solicitation & Information Statement (PSI), which solicits votes and provides necessary information ahead of a meeting. While it relates to an AGM/EGM, the core function here is providing the preparatory materials for the vote, making PSI the most precise fit over AGM-R (which is for the meeting materials themselves) or RNS (which is a general fallback). The document is not the full report (10-K, IR) nor is it just a notice of dividend or management change.
2019-10-22 English
PR_2019-10-22_BT_EGM3_2019-11-22_Notice_FR_Final.pdf
AGM Information Classification · 98% confidence The document is titled "Mise à disposition des documents préparatoires à l'assemblée générale extraordinaire du 22 novembre 2019" (Making available of preparatory documents for the Extraordinary General Meeting of November 22, 2019). It explicitly states that the notice of the EGM, including the agenda and draft resolutions, is being published, and that the preparatory documents are made available to shareholders on the website and upon request. This structure—announcing the availability of materials for an upcoming shareholder meeting—is characteristic of a Proxy Solicitation & Information Statement (PSI) or, given the context of making documents available for a general meeting, it strongly aligns with the purpose of materials distributed before an AGM/EGM. Since the document is an announcement about the availability of materials for a General Meeting (Extraordinary General Meeting), the most fitting category is AGM-R (AGM Information), as it pertains directly to the materials prepared for that meeting, even if it's an announcement of availability rather than the full presentation itself. However, the core action described is the 'making available' of preparatory documents for a shareholder meeting, which is a key component of proxy materials. Given the options, AGM-R covers the subject matter (AGM documents), but the document itself is an announcement about the availability of those documents. If the document were the actual voting results, it would be DVA. If it were the formal solicitation for votes, it would be PSI. Since it is announcing the availability of the preparatory documents for the EGM, AGM-R is the best fit for the subject matter, although RPA could also be considered if the focus was purely on the announcement mechanism. Given the specific mention of the EGM and its preparatory documents, AGM-R is chosen.
2019-10-22 French
Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Bone Therapeutics regarding a change in the total number of voting rights and shares following the conversion of convertible bonds. This type of disclosure is a standard regulatory requirement for listed companies to inform the market about changes in capital structure and share counts. It fits the definition of a 'Share Issue/Capital Change' (SHA) announcement as it details the issuance of new shares and the resulting impact on the company's capital and voting rights.
2019-10-03 French
Bone Therapeutics SA: Information on the total number of voting rights and shares
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated October 3, 2019, announcing an increase in the total number of voting rights and shares due to the issuance of new shares following the conversion of convertible bonds. It explicitly states that the information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on a regulated market. The core content involves detailed tables showing changes in share capital, total shares with voting rights, and potential shares from warrants/convertible bonds. This directly relates to changes in the company's capital structure and share count, fitting the definition of 'Share Issue/Capital Change' (SHA). It is not a general earnings release (ER), an interim report (IR), or a formal 10-K.
2019-10-03 English
PR_2019-10-03_BT_CB Denominator_EN_Final.pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information on the total number of voting rights and shares" and explicitly states it is publishing information in accordance with Article 15 of the Belgian Law regarding the publication of major shareholdings. It details changes in share capital, the total number of shares with voting rights, and potential shares that could be created upon warrant exercise or bond conversion. This content directly relates to changes in the company's capital structure and share count, which falls under the category of Share Issue/Capital Change (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple announcement of a report (RPA).
2019-10-03 English
PR_2019-10-03_BT_CB Denominator_FR_Final.pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions" (Information relating to the total number of voting rights and shares) and explicitly states it is published in accordance with Belgian law regarding the declaration of significant shareholdings. It details the change in the total number of shares and voting rights following the issuance of new shares due to the conversion of convertible bonds. This content directly relates to changes in the company's capital structure and share count, which aligns perfectly with the 'Share Issue/Capital Change' definition (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend announcement (DIV).
2019-10-03 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.